Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed EPS (Basic) for 16 consecutive years, with $0.43 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 6.52% year-over-year to $0.43, compared with a TTM value of $1.75 through Dec 2025, up 26.81%, and an annual FY2025 reading of $1.75, up 26.81% over the prior year.
  • EPS (Basic) was $0.43 for Q4 2025 at Catalyst Pharmaceuticals, up from $0.42 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.47 in Q1 2025 and bottomed at -$0.3 in Q3 2023.
  • Average EPS (Basic) over 5 years is $0.25, with a median of $0.26 recorded in 2022.
  • The sharpest move saw EPS (Basic) tumbled 236.36% in 2023, then soared 223.33% in 2024.
  • Year by year, EPS (Basic) stood at $0.09 in 2021, then skyrocketed by 166.67% to $0.24 in 2022, then skyrocketed by 37.5% to $0.33 in 2023, then surged by 39.39% to $0.46 in 2024, then decreased by 6.52% to $0.43 in 2025.
  • Business Quant data shows EPS (Basic) for CPRX at $0.43 in Q4 2025, $0.42 in Q3 2025, and $0.43 in Q2 2025.